A groundbreaking collaboration between Australian biopharmaceutical leader Telix Pharmaceuticals and Germany's University Hospital Essen is set to revolutionize prostate cancer management through AI-enabled prostate cancer imaging. The partnership centers on the PROMISE-PET registry study, harnessing a vast dataset of over 15,000 standardized PSMA-PET scans to develop advanced AI prediction models for patient survival.
This development holds particular promise for Australia, where prostate cancer remains the most common cancer among men, with an estimated 28,868 new cases in 2025 alone and around 3,975 deaths projected that year. As Telix, headquartered in Melbourne, drives this innovation, it underscores the growing role of Australian biotech in global oncology research, potentially paving the way for enhanced diagnostic tools in local universities and hospitals.
Understanding PSMA-PET Imaging in Prostate Cancer Diagnosis
Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) represents a leap forward in prostate cancer imaging. Unlike traditional CT or bone scans, PSMA-PET targets prostate-specific membrane antigen (PSMA), a protein overexpressed on prostate cancer cells, using radiotracers like gallium-68 PSMA-11 (Telix's Illuccix®). This allows for precise detection of primary tumors, lymph node involvement, and distant metastases, even at low PSA levels.
In Australia, Illuccix has been TGA-approved since 2021 and Medicare-funded since 2022, enabling widespread access for staging and recurrence detection. The process involves injecting the tracer, which binds to PSMA-positive cells, followed by PET scanning to visualize uptake. High uptake indicates cancer activity, guiding biopsy avoidance or targeted therapies.
For patients, this means fewer invasive procedures and personalized treatment plans, critical given Australia's high incidence rates—one in five men diagnosed by age 85.
The PROMISE-PET Registry: A Global Dataset Powerhouse
Launched in 2018, PROMISE-PET (PROstate cancer Molecular Imaging Standardized Evaluation-PET) is a prospective, observational registry collecting data from over 15,000 patients across 50+ institutions worldwide. Standardized using the PROMISE criteria (revised 2023), it links imaging findings to long-term outcomes, establishing PSMA-PET as a prognostic biomarker.
At University Hospital Essen, led by Prof. Michael Schäfers and Dr. Heinrich Ruehs, the registry has redefined staging and risk assessment. Publications validate its use in survival prediction, now enhanced by Telix's involvement. The free ePROMISE web app standardizes readings, making it accessible for clinicians globally, including Australian researchers.
This resource could inspire similar registries at Australian centers like Peter MacCallum Cancer Centre, fostering data-driven insights.
AI's Transformative Role in Prostate Cancer Prognostics
Artificial Intelligence (AI) analyzes complex PSMA-PET data to predict outcomes beyond human capability. Telix's AutoML engine will process PROMISE-PET scans to build survival models, outperforming traditional nomograms like MSKCC or Briganti.
Step-by-step, AI segments lesions, quantifies uptake (SUVmax), assesses tumor burden, and integrates clinical data for risk stratification. Validation against real-world outcomes ensures reliability. Prof. Wolfgang Fendler notes, “Telix’s AI platform... will leverage one of the world’s largest PSMA-PET datasets to support improved risk stratification.”
In Australia, where 96% five-year survival hinges on early detection, such tools could optimize therapies like Lutetium-177 PSMA.Cancer Australia Statistics
Photo by Vitaly Gariev on Unsplash
Telix Pharmaceuticals: Australia's Radiopharma Pioneer
Telix, ASX-listed and Melbourne-based, leads in targeted radiopharmaceuticals. Illuccix powers PSMA-PET globally, with approvals in Australia, US, Canada. Ongoing trials like BiPASS (Phase 3, biopsy avoidance) and ProstACT GLOBAL (therapeutics) involve Australian sites.
Simon Wail, Telix AI Director, highlights the registry's value: “...build, test and validate clinically relevant prognostic models.” Telix's university ties, including a 2017 partnership with University of Melbourne for PET imaging tech (89Zr chemistry) and Peter MacCallum, exemplify industry-academia synergy.
Check research jobs in radiopharma at Australian unis.
Prostate Cancer Landscape in Australia: Stats and Challenges
- 2025 estimates: 28,868 new cases (30% of male cancers), 3,975 deaths (13% of male cancer deaths).
- 1 in 5 men diagnosed by 85; 96% 5-year survival (up from 60% in 1980s).
- 106,705 living with diagnosis (2021).
Rising incidence demands better imaging; PSMA-PET uptake surged post-Medicare.
Stakeholders like Prostate Cancer Foundation Australia advocate AI integration for equitable access.
Australian Universities Leading AI Prostate Cancer Research
Aussie unis pioneer AI-PSMA-PET. Monash University's thesis integrates PSMA-PET AI for focal therapy selection, improving accuracy by detecting occult disease.
St Vincent's Hospital Melbourne and RMIT's AI analyzes CT scans for asymptomatic detection, outperforming radiologists. Peter MacCallum and UMelb collaborate with Telix on imaging agents.
These efforts position Australia at the forefront, with opportunities in clinical research jobs.
Implications and Future Outlook for Global Collaboration
The Telix-PROMISE partnership could redefine guidelines, influencing Australian practices. Upcoming Telix trials (BiPASS in Aus/US) test PSMA-PET for initial diagnosis.
Challenges: Data standardization, AI validation, equitable access. Solutions: Uni-industry hubs like Bio21 (UMelb).
Future: AI-driven theranostics, reducing overtreatment. PROMISE-PET, Telix Prostate.
Career Opportunities in AI-Enabled Medical Imaging
Australia's boom in AI oncology creates demand for researchers, data scientists. Unis like Monash, UMelb seek talent in PSMA-PET AI.
- Skills: Machine learning, radiomics, clinical trials.
- Risks: Ethical AI, data privacy.
- Benefits: High-impact publications, industry roles.
Explore university jobs, research positions, or academic CV tips.
Actionable Insights for Researchers and Clinicians
- Adopt PROMISE criteria for PSMA-PET reporting. - Leverage AutoML for prognostic modeling. - Join trials like BiPASS for hands-on experience.
Australia's higher ed stands ready to advance AI-enabled prostate cancer imaging, blending Telix's innovation with uni expertise for better patient outcomes.
Visit Rate My Professor for insights, higher ed jobs, or career advice.
